Nasdaq · CIK 0002012593
RAPP Rapport Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 4 d ago. Close $30.65 on Oct 9, 2026, +26% from the 52-week low and -42% from the high.
Last 90 days
Net insider value
-$936k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
4
$936k by 2 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
RAPPOct 9, 2026 · close 30.65
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Rapport Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 24Weak | Abraham Ceesay Chief Executive Officer sell | $143k 4,522 shares | -1% | +28% from low-41% from high | |
| 23Weak | Cheryl Gault Chief Operating Officer sell | $332k 10,000 shares | -7% | +38% from low-36% from high | |
| 22Weak | Abraham Ceesay Chief Executive Officer sell | $87k 2,210 shares | -0% | +40% from low-35% from high | |
| 20Weak | Abraham Ceesay Chief Executive Officer sell | $374k 8,210 shares | -2% | - | |
| 22Weak | Cheryl Gault Chief Operating Officer sell | $282k 10,000 shares | -6% | +235% from low-13% from high | |
| 17Weak | Krishnaswamy Yeleswaram Chief Development Officer sell | $303k 10,115 shares | -3% | +249% from low-9% from high | |
| 27Weak | Cheryl Gault Chief Operating Officer sell | $58k 2,014 shares | -1% | +267% from low-7% from high | |
| 1Weak | David Bredt Chief Scientific Officer sell | $247k 8,500 shares | -2% | +306% from low-9% from high | |
| 27Weak | Abraham Ceesay Chief Executive Officer sell | $320k 10,916 shares | -2% | +308% from low-8% from high | |
| 27Weak | Abraham Ceesay Chief Executive Officer sell | $285k 10,916 shares | -2% | +263% from low-19% from high | |
| 16Weak | David Bredt Chief Scientific Officer sell | $228k 8,500 shares | -2% | +276% from low-16% from high | |
| 42Moderate | David Bredt Chief Scientific Officer sell | $197k 6,567 shares | -2% | +324% from low-5% from high | |
| 39Weak | Krishnaswamy Yeleswaram Chief Development Officer sell | $85k 2,840 shares | -1% | +324% from low-5% from high | |
| 34Weak | Abraham Ceesay Chief Executive Officer sell | $324k 10,916 shares | -2% | +301% from low-9% from high | |
| 16Weak | David Bredt Chief Scientific Officer sell | $255k 8,500 shares | -2% | +314% from low-6% from high | |
| 11Weak | Cheryl Gault Chief Operating Officer sell | $150k 5,000 shares | -3% | +312% from low-6% from high | |
| 22Weak | David Bredt Chief Scientific Officer sell | $214k 8,500 shares | -2% | +251% from low-20% from high | |
| 34Weak | Abraham Ceesay Chief Executive Officer sell | $275k 10,916 shares | -2% | +251% from low-20% from high | |
| 15Weak | David Bredt Chief Scientific Officer sell | $219k 8,500 shares | -2% | +261% from low-18% from high | |
| 27Weak | Abraham Ceesay Chief Executive Officer sell | $282k 10,916 shares | -2% | +261% from low-18% from high | |
| 50Moderate | Abraham Ceesay Chief Executive Officer sell | $2.0M 76,420 shares | -12% | +268% from low-16% from high | |
| 22Weak | David Bredt Chief Scientific Officer sell | $206k 8,500 shares | -2% | +246% from low-21% from high | |
| 60Notable | Reid M Huber director buy | $499k 20,400 shares | - | +232% from low-25% from high | |
| 67Notable | Steven M Paul director buy | $1.0M 41,666 shares | - | +232% from low-25% from high | |
| 53Moderate | Wendy B. Young director buy | $79k 3,500 shares | +58% | +224% from low-26% from high | |
| 12Weak | Cheryl Gault Chief Operating Officer sell | $192k 5,000 shares | -3% | +340% from low0% from high | |
| 6Weak | David Bredt Chief Scientific Officer sell | $127k 8,500 shares | -2% | +106% from low-50% from high | |
| 5Weak | David Bredt Chief Scientific Officer sell | $119k 8,500 shares | -2% | +101% from low-51% from high | |
| 5Weak | David Bredt Chief Scientific Officer sell | $94k 8,500 shares | -2% | +57% from low-62% from high | |
| 4Weak | David Bredt Chief Scientific Officer sell | $81k 8,500 shares | -2% | +36% from low-67% from high | |
| 4Weak | David Bredt Chief Scientific Officer sell | $81k 8,500 shares | -2% | +34% from low-67% from high | |
| 4Weak | David Bredt Chief Scientific Officer sell | $92k 8,500 shares | -2% | - | |
| 40Moderate | Troy A. Ignelzi Chief Financial Officer buy | $101k 10,000 shares | - | - |
Transactions
The last 99 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -3,375 | $32.03 | $108k | 453,392 | 4 d ago |
| Oct 7, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -1,147 | $30.66 | $35k | 452,245 | 4 d ago |
| Sep 30, 2026 | Cheryl Gault Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -7,925 | $33.04 | $262k | 141,989 | 11 d ago |
| Sep 30, 2026 | Cheryl Gault Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -2,075 | $33.76 | $70k | 139,914 | 11 d ago |
| Sep 23, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -1,952 | $39.05 | $76k | 457,025 | 18 d ago |
| Sep 23, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -215 | $39.86 | $8,570 | 456,810 | 18 d ago |
| Sep 23, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -43 | $41.05 | $1,765 | 456,767 | 18 d ago |
| Sep 8, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -7,141 | $45.56 | $325k | 460,046 | 33 d ago |
| Sep 8, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -1,069 | $46.01 | $49k | 458,977 | 33 d ago |
| Mar 30, 2026 | Cheryl Gault Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -7,161 | $28.04 | $201k | 162,753 | Mar 31, 2026 |
| Mar 30, 2026 | Cheryl Gault Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -2,839 | $28.55 | $81k | 159,914 | Mar 31, 2026 |
| Mar 25, 2026 | Krishnaswamy Yeleswaram Chief Development Officer | SOpen-market sale Common Stock10b5-1 | -10,115 | $29.99 | $303k | 286,876 | Mar 26, 2026 |
| Mar 5, 2026 | Cheryl Gault Chief Operating Officer | SOpen-market sale Common Stock | -2,014 | $28.93 | $58k | 169,914 | Mar 9, 2026 |
| Feb 18, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -3,552 | $29.05 | $103k | 558,528 | Feb 19, 2026 |
| Feb 17, 2026 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -900 | $28.02 | $25k | 394,675 | Feb 19, 2026 |
| Feb 17, 2026 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -5,400 | $28.95 | $156k | 389,275 | Feb 19, 2026 |
| Feb 18, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -2,281 | $29.80 | $68k | 556,247 | Feb 19, 2026 |
| Feb 17, 2026 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -2,200 | $29.59 | $65k | 387,075 | Feb 19, 2026 |
| Feb 18, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,983 | $29.04 | $87k | 22,829 | Feb 19, 2026 |
| Feb 18, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,100 | $29.80 | $63k | 20,729 | Feb 19, 2026 |
| Feb 19, 2026 | David Bredt Chief Scientific Officer | MOption exercise Common Stock10b5-1 | +6,000 | $1.80 | $11k | 393,075 | Feb 19, 2026 |
| Feb 19, 2026 | David Bredt Chief Scientific Officer | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 88,080 | Feb 19, 2026 |
| Feb 2, 2026 | Jeffrey Sevigny Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Feb 4, 2026 |
| Feb 2, 2026 | Krishnaswamy Yeleswaram Chief Development Officer | AGrant or award Stock Option (Right to Buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Feb 4, 2026 |
| Feb 2, 2026 | Troy A. Ignelzi Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +148,000 | $0.00 | $0 | 148,000 | Feb 4, 2026 |
| Feb 2, 2026 | Abraham Ceesay Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +428,000 | $0.00 | $0 | 428,000 | Feb 4, 2026 |
| Feb 2, 2026 | David Bredt Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +103,000 | $0.00 | $0 | 103,000 | Feb 4, 2026 |
| Feb 2, 2026 | Cheryl Gault Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +132,000 | $0.00 | $0 | 132,000 | Feb 4, 2026 |
| Jan 20, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -5,833 | $26.12 | $152k | 562,080 | Jan 22, 2026 |
| Jan 20, 2026 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -5,083 | $26.11 | $133k | 25,812 | Jan 22, 2026 |
| Jan 15, 2026 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,300 | $26.83 | $223k | 395,775 | Jan 16, 2026 |
| Jan 15, 2026 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -200 | $27.40 | $5,480 | 395,575 | Jan 16, 2026 |
| Dec 31, 2025 | David Bredt Chief Scientific Officer | AGrant or award Common Stock | -18,000 | - | - | 410,642 | Jan 5, 2026 |
| Dec 31, 2025 | Krishnaswamy Yeleswaram Chief Development Officer | AGrant or award Common Stock | +9,000 | - | - | 299,831 | Jan 5, 2026 |
| Dec 31, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock | -6,567 | $30.05 | $197k | 404,075 | Jan 5, 2026 |
| Dec 31, 2025 | Krishnaswamy Yeleswaram Chief Development Officer | SOpen-market sale Common Stock | -2,840 | $30.05 | $85k | 296,991 | Jan 5, 2026 |
| Dec 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -2,441 | $28.84 | $70k | 571,305 | Dec 18, 2025 |
| Dec 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -2,792 | $30.04 | $84k | 568,513 | Dec 18, 2025 |
| Dec 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -600 | $31.04 | $19k | 567,913 | Dec 18, 2025 |
| Dec 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,147 | $28.84 | $62k | 33,831 | Dec 18, 2025 |
| Dec 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,421 | $30.04 | $73k | 31,410 | Dec 18, 2025 |
| Dec 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -515 | $31.04 | $16k | 30,895 | Dec 18, 2025 |
| Dec 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -7,704 | $29.95 | $231k | 393,438 | Dec 16, 2025 |
| Dec 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -796 | $30.68 | $24k | 392,642 | Dec 16, 2025 |
| Nov 26, 2025 | Cheryl Gault Chief Operating Officer | MOption exercise Common Stock10b5-1 | +5,000 | $1.80 | $9,000 | 176,928 | Dec 1, 2025 |
| Nov 26, 2025 | Cheryl Gault Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -5,000 | $30.10 | $150k | 171,928 | Dec 1, 2025 |
| Nov 26, 2025 | Cheryl Gault Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 105,407 | Dec 1, 2025 |
| Nov 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -2,777 | $24.92 | $69k | 576,802 | Nov 18, 2025 |
| Nov 17, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,156 | $24.84 | $78k | 406,486 | Nov 18, 2025 |
| Nov 17, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -5,344 | $25.39 | $136k | 401,142 | Nov 18, 2025 |
| Nov 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -3,056 | $25.43 | $78k | 573,746 | Nov 18, 2025 |
| Nov 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,242 | $24.91 | $56k | 38,819 | Nov 18, 2025 |
| Nov 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -2,841 | $25.44 | $72k | 35,978 | Nov 18, 2025 |
| Oct 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -7,418 | $25.73 | $191k | 410,724 | Oct 16, 2025 |
| Oct 15, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -4,647 | $25.72 | $120k | 580,765 | Oct 16, 2025 |
| Oct 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -1,082 | $26.16 | $28k | 409,642 | Oct 16, 2025 |
| Oct 15, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -1,186 | $26.14 | $31k | 579,579 | Oct 16, 2025 |
| Oct 15, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -4,328 | $25.75 | $111k | 41,816 | Oct 16, 2025 |
| Oct 15, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -755 | $26.17 | $20k | 41,061 | Oct 16, 2025 |
| Sep 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -39,435 | $26.30 | $1.0M | 586,812 | Sep 19, 2025 |
| Sep 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -1,400 | $26.87 | $38k | 585,412 | Sep 19, 2025 |
| Sep 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -34,885 | $26.30 | $918k | 46,844 | Sep 19, 2025 |
| Sep 17, 2025 | Abraham Ceesay Chief Executive Officer | SOpen-market sale Common Stockindirect: By Dorothy Ceesay Irrevocable Trust10b5-1 | -700 | $27.04 | $19k | 46,144 | Sep 19, 2025 |
| Sep 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -5,098 | $23.88 | $122k | 421,544 | Sep 17, 2025 |
| Sep 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,402 | $24.66 | $84k | 418,142 | Sep 17, 2025 |
| Sep 12, 2025 | Reid M Huber director | POpen-market purchase Common Stock | +20,400 | $24.48 | $499k | 20,400 | Sep 15, 2025 |
| Sep 12, 2025 | Steven M Paul director | POpen-market purchase Common Stockindirect: By Paul Capital Strategy III Fund LLC | +28,284 | $24.50 | $693k | 28,284 | Sep 15, 2025 |
| Sep 12, 2025 | Steven M Paul director | POpen-market purchase Common Stockindirect: By Paul Capital Strategy III Fund LLC | +13,382 | $24.97 | $334k | 41,666 | Sep 15, 2025 |
| Sep 11, 2025 | Wendy B. Young director | POpen-market purchase Common Stock | +3,500 | $22.60 | $79k | 9,500 | Sep 11, 2025 |
| Sep 8, 2025 | Cheryl Gault Chief Operating Officer | MOption exercise Common Stock10b5-1 | +5,000 | $1.80 | $9,000 | 176,928 | Sep 10, 2025 |
| Sep 8, 2025 | Cheryl Gault Chief Operating Officer | SOpen-market sale Common Stock10b5-1 | -5,000 | $38.33 | $192k | 171,928 | Sep 10, 2025 |
| Sep 8, 2025 | Cheryl Gault Chief Operating Officer | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 110,407 | Sep 10, 2025 |
| Aug 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,300 | $14.98 | $124k | 426,842 | Aug 18, 2025 |
| Aug 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -200 | $15.79 | $3,158 | 426,642 | Aug 18, 2025 |
| Jul 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,500 | $14.00 | $119k | 435,142 | Jul 16, 2025 |
| Jun 17, 2025 | James Healy director | AGrant or award Stock Option (Right to Buy)derivative | +21,850 | $0.00 | $0 | 21,850 | Jun 18, 2025 |
| Jun 17, 2025 | Reid M Huber director | AGrant or award Stock Option (Right to Buy)derivative | +21,850 | $0.00 | $0 | 21,850 | Jun 18, 2025 |
| Jun 17, 2025 | John Maraganore director | AGrant or award Stock Option (Right to Buy)derivative | +21,850 | $0.00 | $0 | 21,850 | Jun 18, 2025 |
| Jun 17, 2025 | Steven M Paul director | AGrant or award Stock Option (Right to Buy)derivative | +21,850 | $0.00 | $0 | 21,850 | Jun 18, 2025 |
| Jun 17, 2025 | Robert J Perez director | AGrant or award Stock Option (Right to Buy)derivative | +10,925 | $0.00 | $0 | 10,925 | Jun 18, 2025 |
| Jun 17, 2025 | Paul M Silva director | AGrant or award Stock Option (Right to Buy)derivative | +10,925 | $0.00 | $0 | 10,925 | Jun 18, 2025 |
| Jun 17, 2025 | Wendy B. Young director | AGrant or award Stock Option (Right to Buy)derivative | +10,925 | $0.00 | $0 | 10,925 | Jun 18, 2025 |
| Jun 17, 2025 | Ramiro Sanchez director | AGrant or award Stock Option (Right to Buy)derivative | +10,925 | $0.00 | $0 | 10,925 | Jun 18, 2025 |
| Jun 16, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,500 | $11.00 | $94k | 443,642 | Jun 18, 2025 |
| May 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,500 | $9.56 | $81k | 452,142 | May 19, 2025 |
| Apr 15, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,500 | $9.57 | $81k | 460,642 | Apr 16, 2025 |
| Apr 1, 2025 | Jeffrey Sevigny Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Apr 3, 2025 |
| Mar 14, 2025 | David Bredt Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -8,500 | $10.85 | $92k | 469,142 | Mar 17, 2025 |
| Mar 12, 2025 | Troy A. Ignelzi Chief Financial Officer | POpen-market purchase Common Stock | +9,900 | $10.10 | $100k | 9,900 | Mar 13, 2025 |
| Mar 13, 2025 | Troy A. Ignelzi Chief Financial Officer | POpen-market purchase Common Stock | +100 | $9.98 | $998 | 10,000 | Mar 13, 2025 |
| Mar 3, 2025 | Cheryl Gault Chief Operating Officer | AGrant or award Common Stock | +13,987 | $0.00 | $0 | 171,928 | Mar 5, 2025 |
| Feb 3, 2025 | David Bredt Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 4, 2025 |
| Feb 3, 2025 | Abraham Ceesay Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +428,000 | $0.00 | $0 | 428,000 | Feb 4, 2025 |
| Feb 3, 2025 | Cheryl Gault Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +129,000 | $0.00 | $0 | 129,000 | Feb 4, 2025 |
| Feb 3, 2025 | Troy A. Ignelzi Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +142,000 | $0.00 | $0 | 142,000 | Feb 4, 2025 |
| Nov 7, 2024 | Robert J Perez director | AGrant or award Stock Option (Right to Buy)derivative | +29,756 | $0.00 | $0 | 29,756 | Nov 7, 2024 |
| Nov 7, 2024 | Ramiro Sanchez director | AGrant or award Stock Option (Right to Buy)derivative | +29,756 | $0.00 | $0 | 29,756 | Nov 7, 2024 |
| Nov 7, 2024 | Paul M Silva director | AGrant or award Stock Option (Right to Buy)derivative | +29,756 | $0.00 | $0 | 29,756 | Nov 7, 2024 |
| Nov 7, 2024 | Wendy B. Young director | AGrant or award Stock Option (Right to Buy)derivative | +29,756 | $0.00 | $0 | 29,756 | Nov 7, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- David BredtChief Scientific Officer
- Abraham CeesayChief Executive Officer
- Cheryl GaultChief Operating Officer
- James Healydirector
- Reid M Huberdirector
- Troy A. IgnelziChief Financial Officer
- John Maraganoredirector
- Steven M Pauldirector
- Robert J Perezdirector
- Ramiro Sanchezdirector
- Jeffrey SevignyChief Medical Officer
- Paul M Silvadirector
- Krishnaswamy YeleswaramChief Development Officer
- Wendy B. Youngdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.